Research monograph · synthetic ghrh(1-44) analog (trans-3-hexenoic acid-modified)
Growth Hormone Release Studies
This monograph collects what the published literature reports about Tesamorelin — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Unlike shorter GHRH fragments, it preserves the complete native sequence, and research examines growth hormone release and visceral adipose endpoints.
For laboratory research use only — not for human or animal use
Mechanisms
Growth Hormone Secretagogue
A synthetic GHRH matching the full 44-residue human sequence, with a trans-3-hexenoyl group at the N-terminus to resist degradation. Unlike shorter fragments it preserves the complete native sequence.
Visceral Adipose Reduction
Visceral adipose tissue is the endpoint with the largest clinical dataset behind this compound, and the one that distinguishes it from other GHRH analogues in the literature.
Cognitive & Brain Research
A smaller body of work examines cognitive endpoints on the basis that growth hormone signalling reaches the central nervous system. Findings here are preliminary relative to the adipose data.
Studied applications
Visceral adipose tissue carries the largest clinical dataset for this compound and distinguishes it from other GHRH analogues.
Falutz et al. 2010
Cognitive and imaging endpoints are examined on the basis that growth hormone signalling reaches the central nervous system.
Baker et al. 2019
IGF-1 is measured as the downstream marker of release, as with every compound acting upstream of the pituitary.
Stanley et al. 2011
Lipid profiles are tracked alongside body composition, since the two move together in this literature.
Falutz et al. 2014
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Sequence | Modified GHRH(1-44) analog (44 amino acids) |
|---|---|
| Molecular weight | 5,135.80 g/mol |
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| Available sizes | 10mg |
FAQ
Tesamorelin is a synthetic GHRH matching the full 44-residue human sequence, with a trans-3-hexenoyl group added at the N-terminus to resist enzymatic degradation. Unlike shorter GHRH fragments, it preserves the complete native sequence, and research examines growth hormone release and visceral adipose endpoints.
Published research on Tesamorelin concentrates on Visceral Fat & Body Composition, Brain Structure & Function, GH/IGF-1 Axis and Lipid & Cardiovascular Markers. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes Tesamorelin acting across Growth Hormone Secretagogue, Visceral Adipose Reduction and Cognitive & Brain Research, reported respectively as GHRH-R Agonism, Lipolysis and Neuroprotection. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
Tesamorelin has a molecular formula of C221H366N72O67S, an average mass of 5135.89 g/mol and the sequence Modified GHRH(1-44) analog (44 amino acids). It is indexed under CAS 218949-48-5. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Tesamorelin is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. Tesamorelin is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
